Filing Flows › Integra Lifesciences Holdings (IART) › Q1 2025
Integra Lifesciences Holdings (IART) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 5, 2025
Integra Lifesciences Holdings (IART) reported revenue of $383M for the first quarter 2025 (Q1 2025), +4% from a year earlier and -14% from the quarter before. Operating margin was -4.0%, net loss $25.3M (6.6% of revenue).
Integra Lifesciences Holdings, Q1 2025: revenue $383M (+4% year over year), operating margin -4.0%, net loss $25.3M, operating cash flow −$11.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $383M | -14% | +4% |
| Operating profit | −$15.5M | — | — |
| Net earnings | −$25.3M | — | — |
| Operating cash flow | −$11.3M | — | — |
What changed
Revenue was $382.7M in Q1 2025, up 4% year over year and down 14% from the previous quarter. Codman Specialty Surgical was the largest line at 73% of revenue. Codman Specialty Surgical added $24.2M year over year (up 9%), 176% of the total change. Tissue Technologies declined 9%.
Operating costs exceeded revenue by $15.5M, an operating margin of -4.0%. Total costs grew 9% against revenue growth of 4%. The fastest-growing cost line was Cost of revenue (+16%). The quarter ended with a net loss of $25.3M, after a profit of $19.4M the previous quarter. Net interest and other expense of $14.5M was the main reason.
Operating cash flow was −$11.3M. Non-cash charges added back $1.9M of share-based compensation. Working capital and other items added $12.2M. Capital expenditures of $28.9M exceeded it, leaving free cash flow of −$40.2M.
Questions
What was Integra Lifesciences Holdings' revenue in the first quarter 2025?
Integra Lifesciences Holdings (IART) reported revenue of $383M for the first quarter 2025 (Q1 2025), +4% from a year earlier and -14% from the quarter before.
Was Integra Lifesciences Holdings profitable in the first quarter 2025?
Operating loss was $15.5M (-4.0% of revenue) and net loss $25.3M.